SIREN : 834063679
BIO GRAND LARGE is a French company founded 8 years ago, specialized in the sector Supérettes. Based in MEYZIEU (69330), this company of category PME shows in 2025 a revenue of 1.9 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2022 | 2018 |
|---|---|---|---|---|---|
| Revenue | 1 907 581 € | 1 777 162 € | 1 683 140 € | 1 982 101 € | 17 909 € |
| Net income | 59 393 € | 27 359 € | 35 432 € | 23 369 € | -10 000 € |
| EBITDA | 250 289 € | 205 664 € | 170 690 € | 261 965 € | -16 525 € |
| Net margin | 3.1% | 1.5% | 2.1% | 1.2% | -55.8% |
In 2025, BIO GRAND LARGE achieves revenue of 1.9 M€. Over the period 2018-2025, the company shows strong growth with a CAGR (compound annual growth rate) of +94.8%. Vs 2024: +7%. After deducting consumption (1.3 M€), gross margin stands at 616 k€, i.e. a rate of 32%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 250 k€, representing 13.1% of revenue. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 59 k€, i.e. 3.1% of revenue. This profit can be retained or distributed to shareholders.
1 907 581 €
615 823 €
250 289 €
74 748 €
59 393 €
13.1%
The debt ratio (= Financial debt / Equity x 100) stands at 71%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 43%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 2.1 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 4.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
71.12%
42.859%
4.494%
2.076
25.5%
In 2025, the debt ratio of BIO GRAND LARGE (71.12) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2025, the financial autonomy of BIO GRAND LARGE (42.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2025, the repayment capacity of BIO GRAND LARGE (2.08) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 215.80. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.5x. Danger: operating income does not cover interest charges, unsustainable situation.
215.797
0.453
In 2025, the liquidity ratio of BIO GRAND LARGE (215.80) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2025, the interest coverage of BIO GRAND LARGE (0.5x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 27 days. Favorable situation: supplier credit is longer than customer credit by 27 days. Inventory turnover is 23 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 38 days of revenue, i.e. 203 k€ to permanently finance.
202 948 €
0 j
27 j
23 j
38 j
Based on 270 transactions of similar company sales in 2025, the value of BIO GRAND LARGE is estimated at 824 003 € (range 348 595€ - 1 420 329€). With an EBITDA of 250 289€, the sector multiple of 4.5x is applied. The price/revenue ratio is 0.33x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 270 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare BIO GRAND LARGE with other companies in the same sector:
The revenue of BIO GRAND LARGE in 2025 is 1.9 M€.
Yes, BIO GRAND LARGE generated a net profit of 59 k€ in 2025.
The headquarters of BIO GRAND LARGE is located in MEYZIEU (69330), in the department Rhone.
The tax return of BIO GRAND LARGE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
BIO GRAND LARGE operates in the sector Supérettes (NAF code 47.11C). See the 'Sector positioning' section above to compare the company with its competitors.